From the Journals

BTX Injections Appear Safe for Refractory Digital Ischemia in Systemic Sclerosis

Botulinum toxin injections show strong safety and efficacy as an adjunctive treatment for refractory digital ischemia, ulcers, and gangrene in patients with systemic sclerosis, according to a new JAMA Dermatology meta-analysis.

Share

Systemic sclerosis, or scleroderma, affects around 300,000 Americans, leading to skin hardening and potential complications in blood vessels and organs. A recent study published in JAMA Dermatology indicates that botulinum toxin (BTX) injections are a promising adjunctive treatment for refractory ischemic digital complications among those with systemic sclerosis. The systematic review and meta-analysis revealed high complete response rates for conditions like acute digital ischemia and gangrene, while also noting infrequent adverse effects. Further prospective trials are necessary for validation.

Original Source(s)

BTX Injections Appear Safe for Refractory Digital Ischemia in Systemic Sclerosis

Botulinum toxin injections show strong safety and efficacy as an adjunctive treatment for refractory digital ischemia, ulcers, and gangrene in patients with systemic sclerosis, according to a new JAMA Dermatology meta-analysis.

  • by Jo Cavallo

  • December 15, 2025

  • 3 min

Related Content

Apocrine Gland Changes in Early Hidradenitis Suppurativa

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Alopecia Areata Linked to Mental, Autoimmune Risks